Skip to main content

Table 7 MTHFR polymorphisms in literature

From: A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients

Author Year Polymorphism n Treatment Tumor entity Response (p-value) Prognosis (p-value) Genotypes In P F
Ott [22] 2006 MTHFR C677T 235 neo CTx 135 AEGII/III/GC 0.14 0.14   
     OP 103 AEGII/III/GC - 0.23   
Ott [23] 2011 MTHFR C677T 258 neo CTx AEGI 114 n.s. n.s.   
      AEGII-GC 144 n.s. n.s.   
   MTHFR A1298C 258 neo CTx AEGI 114 n.s. n.s.   
      AEGII-GC 144 n.s. 0.02 AA > CC > AC yes
Huang [28] 2008 MTHFR C677T 116 adj CTx GC   0.04 TT/CT > CC 0.056
Wu [49] 2006 MTHFR C677T 210 neoCTx/RCTx AEGI 174/SCC 36 n.a. n.s.   
   MTHFR A1298C 210 neoCTx/RCTx AEGI 174/SCC36 n.a. 0.011 AC/CC > AA n.a.
Ruzzo [51] 2006 MTHFR C677T 175 pall CTx GC 0.2 n.s.   
Chen [48] 2010 MTHFR A1298C 16/73 pall CTx GC - <0.001 AA > AC/CC n.a.
Lu [54] 2004 MTHFR C677T 75 pall CTx GC 0.001 - TT > CC/CT <0.001
Goekkurt [52] 2009 MTHFR C677T 134 pall CTx AEG/GC 0.214 0.319   
   MTHFR A1298C 134 pall CTx AEG/GC 0.053 0.524   
Goekkurt [55] 2006 MTHFR C677T 52 pall CTx GC 0.099 n.s.   
Shitara [50] 2010 MTHFR C677T 132 pall CTx GC n.a. 0.039 TT > CC/CT  
Lee [53] 2005 MTHFR C677T 40 adj CTx GC   0.90   
  1. neo = neoadjuvant, CTx = chemotherapy, RCTx = radiochemotherapy, OP = primarily resected, adj = adjuvant, pall = palliative, AEG = adenocarcinoma of the esophagus/esophagusgastric junction, GC = gastric cancer, n.s. = not significant, n.a. = not applied, In P F = independent prognostic factor.